Rapid screening for cognitive functions

Cogfirst is a rapid cognitive screening that can be completed independently by a patient.

Hidden brain injuries in the acute phase can be detected within 20 minutes.

  • Median time for taking the test: 20 minutes
    (Q1: 18 minutes / Q3: 23 minutes)
  • Self-evaluation of high-level cognitive functions in 7 tests (attention, memory, executive functions, processing speed).
  • Results are calculated instantly.
  • Facilitating the analysis and monitoring of results from a management platform for healthcare professionals.
  • Two A/B testing versions are available to monitor the patient’s progress in the medium term while limiting the learning effect.

Available on tablets!

7 cognitive tests

  • Visual episodic memory (immediate encoding)
  • Visual episodic memory (delayed recall)
  • Visuospatial working memory
  • Visual selective attention
  • Planning
  • Inhibitory control
  • Mental flexibility
Previous slide
Next slide

A collaborative innovation

Cogfirst is the result of Labcom COG-TOOLKIT (ANR funding), a consortium between the Brain Institute, Humans Matter and practitioners from the Lariboisière hospital (APHP).


The objective of Labcom is to design digital cognitive assessment tools augmented with artificial intelligence in order to better manage personalized cognitive remediation programs and to provide quality data to care networks.

 

The Cogfirst project was led by Dr Camille Heslot, MPR doctor at the Lariboisière APHP hospital. Today, Cogfirst is used in clinical routine to screen for possible cognitive sequelae in neurosurgery patients before their return home.

 

The digitalization and screening and the design of the 7 cognitive tests were carried out by Humans Matter, a European leader in the production of cognitive assessment and rehabilitation tools.

Partners

Awards & Nominations

Winner in Resident Innovation APHP (2022)
SOFMER Innovation Competition (2022)
France Head Trauma Prize (2022)
Handitech Trophy Finalist (2024)
Galien Prize Selection (2024)

Research

The result of collaborative innovation between medical research and industrial expertise, Cogfirst is continuing its development and clinical validation for different therapeutic indications.

Several projects are underway to study its potential in the fields of brain injury, neurodegenerative diseases, psychiatry and oncology.

Cogfirst also represents the potential to develop predictions for the clinical evolution of screened patients.

 

Want to participate in the progress of this project? Contact us!

2021
Feasibility study

CHU Lariboisière, APHP

2023
Normalization study on 420 healthy subjects

Brain Institute

2023
Localization and validation of the English version

Vancouver, Canada

2023
Comparison of Cogfirst x MOCA & MMSE in French-speaking patients in the acute phase following neurosurgery

CHU Lariboisière, APHP

2023
Evaluation of 1-year outcomes of patients assessed by Cogfirst

CHU Lariboisière, APHP

2024
Comparison of sensitivity of Cogfirst versus MOCA

Vancouver, Canada

2021
Feasibility study

CHU Lariboisière, APHP

2023
Normalization study on 420 healthy subjects

Brain Institute

2023
Localization and validation of the English version

Vancouver, Canada

2023
Comparison of Cogfirst x MOCA & MMSE in French-speaking patients in the acute phase following neurosurgery

CHU Lariboisière, APHP

2023
Evaluation of 1-year outcomes of patients assessed by Cogfirst

CHU Lariboisière, APHP

2024
Comparison of sensitivity of Cogfirst versus MOCA

Vancouver, Canada

Norms

406 volunteer subjects were selected from the Brain Institute database.

The test-retest effect at 1 month was verified with 95 participants.

The effects of gender, age, number of years of study, and version of the test were evaluated.

The normalization process was carried out with a generalized linear model (GLM).

Population characteristics:

Aged 18 to 85

[18-35[ 207 (50.99%)
[35-50[ 83 (20.44%)
[50-65[ 66 (16.26%)
[65-85] 50 (12.32%)

Years of study from 0 to 20 years

[0-13[ 140 (34.48%)
[13-17[ 140 (34.48%)
[17-20] 126 (31.03%)

Contact us to learn more!